SOFIE
SOFIE specializes in the production and distribution of radiopharmaceuticals and offers contract manufacturing services for diagnostic and therapeutic compounds. The company is recognized for its innovative FAPI compounds and advanced PET/CT systems.
Radiopharmaceutical Production and Distribution
SOFIE boasts a robust network for the production and distribution of radiopharmaceuticals, encompassing 14 radiopharmacy sites. The company ensures on-time delivery of these critical compounds and maintains a 99% cyclotron uptime, which enables the delivery of more than 400,000 doses annually.
Contract Manufacturing Services
SOFIE offers a range of contract manufacturing services tailored for diagnostic and therapeutic compounds. This diversified service portfolio underscores SOFIE's commitment to supporting medical and scientific communities in their pursuit of advanced healthcare solutions.
Product Lines
SOFIE's product lines include well-known diagnostic compounds such as FDG, Pylarify, and Neuraceq, alongside other vital clinical trial products. These offerings demonstrate the company's expertise and market presence in the radiopharmaceutical sector.
Innovative PET/CT Systems
SOFIE has developed advanced PET/CT systems, including the GNEXT PET/CT, a high-performance microPET scanner, and the G8 PET/CT, recognized as the world's first benchtop PET/CT system. These innovations highlight SOFIE's commitment to advancing diagnostic imaging technology.
FAPI Compounds and Clinical Trials
SOFIE's FAPI compounds, which inhibit the fibroblast activation protein, are significant in cancer targeting and have been imaged in over 500 patients. FAPI-46 and FAPI-74 are in Phase 2 clinical trials in the US, targeting pancreatic ductal adenocarcinoma and gastrointestinal cancers respectively. The company's FAPI compounds have shown equal or superior performance over FDG in various cancer indications.